| Date | Time | Source | Headline | Symbol | Company |
| 09/26/2024 | 6:00AM | GlobeNewswire Inc. | Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/20/2024 | 4:55PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/20/2024 | 4:01PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/13/2024 | 4:02PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/13/2024 | 4:00PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/12/2024 | 10:34PM | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/12/2024 | 8:01PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/11/2024 | 4:40PM | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/11/2024 | 4:04PM | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/11/2024 | 4:01PM | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/10/2024 | 4:06PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/10/2024 | 7:08AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 09/10/2024 | 7:00AM | GlobeNewswire Inc. | Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/27/2024 | 8:00AM | GlobeNewswire Inc. | Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/23/2024 | 5:13PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/23/2024 | 4:13PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/22/2024 | 5:15PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/22/2024 | 4:13PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/21/2024 | 4:38PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/21/2024 | 8:00AM | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/20/2024 | 4:52PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/13/2024 | 7:27AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/13/2024 | 7:15AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 08/13/2024 | 7:00AM | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 06/10/2024 | 7:13AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 06/10/2024 | 7:00AM | GlobeNewswire Inc. | Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 05/21/2024 | 8:45AM | GlobeNewswire Inc. | Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 05/13/2024 | 4:32PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 05/13/2024 | 4:23PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |
| 05/13/2024 | 4:10PM | GlobeNewswire Inc. | Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 | NASDAQ:CNTA | Centessa Pharmaceuticals PLC |